Compare NEN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
| Metric | NEN | GLSI |
|---|---|---|
| Founded | 1977 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 236.2M |
| IPO Year | 1995 | 2020 |
| Metric | NEN | GLSI |
|---|---|---|
| Price | $44.00 | $15.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 1.2K | ★ 118.2K |
| Earning Date | 11-13-2026 | 11-24-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,196,544.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.24 | $7.78 |
| 52 Week High | $71.07 | $34.10 |
| Indicator | NEN | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 32.93 | 43.14 |
| Support Level | N/A | $14.38 |
| Resistance Level | $66.30 | $19.82 |
| Average True Range (ATR) | 0.63 | 1.40 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 0.00 | 15.18 |
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.